Johnson & Johnson’s Opsynvi (macitentan and tadalafil) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension 

Shots:  

• The approval was based on the results from the P-III (A DUE) clinical trial evaluating the safety & efficacy of Opsynvi vs macitentan/tadalafil monotx. in patients with PAH (WHO FC II or III). The 1EP was a change from baseline in Pulmonary Vascular Resistance (PVR) at 16wks. 

• The study depicted a greater reduction in PVR at 16wks. with Opsynvi vs macitentan/tadalafil monotx. The trial thereby met its co-primary endpoints by depicting a significant pulmonary hemodynamic improvement 

• Opsynvi is a combination of macitentan (endothelin receptor antagonist) & tadalafil (phosphodiesterase 5 (PDE5) inhibitor) 

Ref: Johnson & Johnson | Image: Johnson & Johnson| Press Release

Related News:-  Italfarmaco’s Duvyzat Obtains the US FDA’s Approval to Treat Duchenne Muscular Dystrophy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com